Login to Your Account

Financings NEWS

Novan Inc. added its name to the IPO queue, revealing in an S-1 filing that it will seek to raise up to $60 million to advance its nitric oxide platform and programs in five dermatological conditions.

Pittsburgh-based Thar Pharmaceuticals Inc. is hoping to follow a similar public trajectory as one of its competitors in the complex regional pain syndrome (CRPS) space, Axsome Therapeutics Inc., which went public late last year raising about $51 million.

Cleave Biosciences Inc. has completed a $37 million series B financing to support further development of CB-5083, its lead oncology candidate for hematological and solid tumor malignancies and discovery efforts related to its AAA ATPase platform over the next 18 months.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: